Identifying microbiome contributions to xenobiotic metabolism and toxicity
Speaker: Michael Zimmermann (EMBL)
Host: Hannes Link (IMIT)
Ort: Hybridevent
- Hörsaal N2
Hörsaalzentrum Morgenstelle
Auf der Morgenstelle 16
72076 Tübingen
Teilnehmende müssen geimpft oder genesen und zusätzlich negativ getestet sein (2G+). Vor Ort müssen Masken getragen werden. Wir weisen darauf hin, dass die Kontaktdaten der Anwesenden aufgenommen werden. Hierzu stellen wir vor Ort ein Formular zur Verfügung. Auch ein Check-In per QR-Code über die Corona-Warn-App ist vor Ort möglich. Lageplan
- Online via Zoom
Für die Anmeldung und weitere Informationen kontaktieren Sie bitte Lisa Bleul:
Abstract:
Individuals vary widely in their drug responses, which can be dangerous and expensive due to significant treatment delays and adverse effects. Growing evidence implicates the gut microbiome in this variability, however the molecular mechanisms remain mostly unknown. To systematically map the drug metabolizing capacity of the gut microbiota and to assess its potential contribution to drug metabolism, we measured the ability of 76 diverse human gut bacteria to metabolize each of 271 oral drugs. We found that two thirds of these drugs are chemically modified by at least one of the tested microbes. Through combination of high-throughput bacterial genetics with mass spectrometry, we systematically identified drug-metabolizing microbial enzymes. Further, we developed experimental and computational approaches to separate host and gut microbiota contributions to drug metabolism in vivo. These allowed us to quantify and predict microbiota contributions to drug metabolism and toxicity. These causal links between microbiota gene content and metabolic activities connect inter-individual microbiome variability to interpersonal differences in the metabolism of drugs and other xenobiotics.